A wearable pulse oximeter and connected software platform shows patient acceptability in ongoing trials<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, May 19, 2025 (HealthDay News) — A wearable pulse oximeter and connected software platform (Apnimed) shows promise for monitoring obstructive sleep apnea (OSA) and other sleep-related breathing diseases, according to a study presented at the American Thoracic Society 2025 International Conference, held from May 18 to 21 in San Francisco.<\/p>\n
Ketan Mehta, from Apnimed Inc. in Cambridge, Massachusetts, and colleagues developed a connected wearable software platform for use with a wearable proximal finger-mounted pulse oximeter to enable serial overnight recordings of saturation of peripheral oxygen and pulse rate (transmittance-based photoplethysmography) and motion (three-axis accelerometer). The platform was tested in 104 patients with OSA (2,017 overnight recordings) as part of ongoing trials.<\/p>\n
The researchers report that the device was used in several different clinical settings, including to monitor patient response to a pharmacologic treatment program for OSA. As part of the study, patients were asked to wear the device for nine nights during a 47-day period, but 85 percent of patients used the device beyond the recommended nights.<\/p>\n
“These data empower both parties to be informed, and they’re able to have more meaningful conversations,” Mehta said in a statement. “This offers the opportunity for shared decision-making between patient and provider using digital medicine.”<\/p>\n
The study was funded by Apnimed.<\/p>\n